



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 6/00	A1	(11) International Publication Number: WO 88/ 05650 (43) International Publication Date: 11 August 1988 (11.08.88)
(21) International Application Number: PCT/HU88/00003 (22) International Filing Date: 29 January 1988 (29.01.88) (31) Priority Application Number: 360/87 (32) Priority Date: 3 February 1987 (03.02.87) (33) Priority Country: HU (71) Applicant (for all designated States except US): REAN-AL FINOMVEGYSZERGYÁR [HU/HU]; Telepes u. 53, H-1441 Budapest (HU). (72) Inventors; and (75) Inventors/Applicants (for US only) : CSÁNYI, Endre [HU/HU]; Gorkij fasor 40, H-1068 Budapest (HU). CSÁNYI, Gábor [HU/HU]; Reviczky u. 5, H-1088 Budapest (HU). BALOGH, Tibor [HU/HU]; Róbert Károly krt. 12/c, H-1138 Budapest (HU). NAGY, László [HU/HU]; Pasaréti út 67, H-1026 Budapest (HU).		(74) Agent: PATENTBUREAU DANUBIA; P.O. Box 198, H-1368 Budapest (HU). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: NEW DENTAL COMPOSITION AND A PROCESS FOR THE PREPARATION THEREOF		
(57) Abstract Dental composition comprising an anti-osteoporotic agent, an antiphlogistic agent, optionally a natural or synthetic chemotherapeutic agent or local anaesthetic, furthermore one or more known auxiliary agent(s). The invention also relates to a process for the preparation of the above composition.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

NEW DENTAL COMPOSITION AND A PROCESS FOR THE PREPARATION
THEREOF

The invention relates to a new dental composition and to a process for the preparation thereof.

As known, caries is the most widespread endemic disease. It is quite obvious to one skilled in the art that a great deal of teeth could be saved by a preservative treatment performed in due time. In practice, however, patients
5 turn to the dentist only when they suffer from an intolerable pain, i.e. when at least one complication exists, too.

Pain is caused first by pulp hyperaemia, i.e. by the reversible inflammation of the vessels and intravascular nerves of the dental radix. The volume of the narrow pulp canal, closed between hard walls, cannot increase, thus the arteries exert a hard pressure on the veins, which results in an early appearance of venal hyperaemia. At the stage of pulp hyperaemia, however, caries does not reach the pulp, since it is separated from it by a thin healthy layer of dentin.

When caries proceeds, an infectious inflammation appears in the pulp (pulpitis). Of the various forms of pulpitis only the main types are mentioned now. When an acute inflammation exists and the pulp is only partially damaged, dentists endeavour to save the living tooth. When inflammation gets, however, chronic and the pulp is completely damaged, the goal of dental treatment is to render the further treatment painless, to exclude additional complications and to ensure a symptom-free recovery.

In its final stage, pulpitis leads to gangrene. Tooth necrosis does not terminate, however, in the pulp. The defensive mechanism of the organism can act against infections only at territories with good blood supply. Periodontium, which surrounds the tooth, suits this requirement, consequently the next stage is the appearance of periodontitis. At the appearance of this disorder, causing pains even upon touch, pulp itself is no longer sensitive, the subjective symptoms are, however, very painful. The task of dentists is to ensure the quick alleviation of this complaint in the acute stage of inflammation. In chronic stages, however, additional complications must be taken into account. Inflammation may spread over the periodontal bony substance

where it may lead to pathologic osteoporoses (granuloma, cysts).

Several attempts have been made to defend the exacerbation of the above diseases. According to Adler and Záray
5 Konzerváló fogászat (Preservative Dentistry) p. 172 (Medicina, Budapest, 1972) (in Hungarian) 7 pulp canal must be sterilized completely. It is very important that the surrounding tissues be free of inflammation. Therefore pulp canal has been treated with various sterilizing agents, antibiotics
10 and antiphlogistics, utilized most frequently as a liquid composition. A disadvantage of this method is that prolonged activity cannot be ensured.

Utilization of powders or removable pastes in such treatments has also been attempted Fogorvosi Szemle (Dentists' Review) 64, 404 (1971) (in Hungarian) 7, but prolonged
15 effect could not be achieved.

Hungarian patent No. 167,308 suggests the use of pointers comprising a sterilizing (i.e. oxidizing) or antiphlogistic agent and/or an antibiotic in admixture with an
20 inert plastic carrier. Penicillin, chloramphenicol and oxytetracyclin are mentioned as antibiotics, whereas hydrocortisone is mentioned as antiphlogistic agent. The major disadvantage of this method is that it can be applied only for the treatment of excavated pulp canal, furthermore it
25 cannot act against osteoporosis coupled with other complications.

The invention aims at providing a new composition applicable for the treatment of caries and for the healing of acute, subacute or chronic inflammatory lesions of pulp,
30 dental radix or the bony substance surrounding them.

Our extensive experimental work has led to the unexpected recognition that a particular combination, i.e. a combination of ipriflavone (7-isopropoxy-isoflavone) and an antiphlogistic agent can be utilized with good results for the complex treatment of teeth. Depending on the conditions of use, this combination can be supplemented with chemotherapeutic agents, local anaesthetics and known auxiliary agents.

The above combination can be applied successfully in all stages of pulpitis and periodontitis.

Based on the above, the invention relates to a new dental composition comprising an anti-osteoporotic agent, preferably ipriflavone, an antiphlogistic agent, optionally a natural or synthetic chemotherapeutic agent or a local anaesthetic, furthermore one or more known auxiliary agent(s).

The invention also relates to a process for the preparation of the above dental composition. According to the invention 0.1 to 30 % by weight of ipriflavone, 0.5 to 15 % by weight of an antiphlogistic agent, preferably triamcinolone, and optionally one or more natural or synthetic chemotherapeutic agent(s) or local anaesthetic(s) are admixed with auxiliary agents commonly applied in dentistry. As synthetic chemotherapeutic agents e.g. sulphonamides or trimethoprim $\left[\overline{2}, 4\text{-diamino-5-(3', 4', 5'\text{-trimethoxybenzyl})-pyrimidine} \right]$ whereas as natural chemotherapeutic agent e.g. doxycyclin base (an antibiotic) or a salt thereof can be applied. As local anaesthetic $\left[\overline{\text{required}} \right]$ e.g. to prepare a coating for protecting dental stump $\left[\overline{\text{lidocaine}} \right]$ lidocaine can be used. Of the sulphonamides sulphamethoxazole is particularly preferred. The known auxiliary agents for dental purposes are

e.g. zinc oxide, calcium oxide, bismuth oxide, titanium dioxide, eugenol, epoxy resin and dental lacquers.

5 The utilization of more than one active agent in a dental filler has led to particularly advantageous and unexpected results.

The antimicrobial agent with a broad spectrum of activity is utilized to exterminate the pathogens which cause inflammation. The antimicrobial agent alone does not act on the other components of the inflammatory process.

10 Triamcinolone, utilized as antiphlogistic agent, exerts a very strong effect on the inflammatory process: it suppresses the oedema and stops the other inflammatory components, resulting in a quick alleviation of pain and in the cessation of inflammation. It is known, however, that this
15 substance may also enhance the activity of osteoklasts causing osteoporosis in the bony substance e.g. when a triamcinolone-containing filling agent is introduced into the pulp canal after the removal of pulp.

Ipriflavone, one of the members of the combination
20 according to the invention, supplements the effects of the two former components in a particularly advantageous manner: it is able to suppress osteoporosis even alone, furthermore it antagonizes the osteoklast activity-increasing effects of steroidal antiphlogistics.

25 By combining these three types of active agents a series of therapeutic dental fillers, suitable for preserving the teeth in any stage of pulpitis and periodontitis, can be obtained.

The most important advantage provided for by the
30 invention is that the combination can be utilized in several

types of dental diseases. The new combinations can be utilized for the following purposes:

5 1/ In the treatment of pulp hyperaemia and acute partial pulpitis a dental cement comprising 0.1 to 10 %, preferably 0.7 to 2 % of the combination according to the invention should be placed onto the pulp-side wall of the cavity formed by the dentist, wherefrom the active agents enter the pulp and result in a very quick relief of pain and in the suppression of inflammation. Doxycyclin, mentioned
10 as an example of the chemotherapeutic agents, accumulates in the tooth, resulting in a prolonged effect. Upon the effect of ipriflavone the formation of secondary dentin is also to be expected.

15 2/ In chronic total pulpitis the treatment is performed in two steps. First the treatment described in point 1/ above is performed in order to attain a painless stage, thereafter the pulp canal is excavated to prevent the spreading of inflammation, and in the second treatment step the method described in point 3/ below is performed.

20 3/ In the treatment of periodontitis the therapeutic paste (admixed with appropriate auxiliary agents) is applied into the previously cleaned and dried pulp canal. The anti-phlogistic and antimicrobial effects appear quickly, and a very quick relief of pain is to be expected.

25 4/ When the complications of periodontitis are to be avoided or the already existing complications should be suppressed, the reversal of osteoporoses already formed (ostitis diffusa, granuloma, cysts) is to be expected upon a prolonged application of the anti-osteoporotic therapeutic
30 paste. The final root filling is prepared after the termina-

tion of the complete bony defects, utilizing an antibiotic-free composition comprising anti-osteoporotic agents, X-ray contrast materials and carriers.

The invention is elucidated in detail by the aid of the following non-limiting Examples.

Example 1

Preparation of a therapeutic cement

A mixture of 2 g of doxycyclin hyclate, 0.8 g of triamcinolone, 2.0 g of ipriflavone, 80 g of zinc oxide and 15.2 g of calcium oxide (Component "A") is admixed with eugenol (Component "B") in a ratio to obtain a composition with a consistency required in dentistry.

Example 2

Preparation of a therapeutic cement

One proceeds as described in Example 1 with the difference that doxycyclin hyclate is replaced by 2.2 g of trimethoprim.

Example 3

Preparation of a therapeutic paste for sterilizing pulp canal

0.2 g of ipriflavone is admixed with 0.2 g of doxycyclin base, 0.08 g of triamcinolone and 10 g of zinc oxide, and the mixture is completed with eugenol in an amount required to obtain a paste.

Example 4

Preparation of a therapeutic paste for sterilizing pulp canal

One proceeds as described in Example 3 with the difference that sulphamethoxazole is substituted for doxycyclin base.

Example 5Preparation of a root filler

5 0.5 g of ipriflavone are admixed with 0.1 g of triamcinolone, 4.0 g of bismuth oxide, 2.0 g of titanium dioxide and 3.4 g of zinc oxide, and epoxy resin is added to the mixture in an amount to obtain a paste.

Example 6Preparation of a coating composition for protecting dental stump

10 A mixture of 0.3 g of ipriflavone, 0.1 g of triamcinolone and 0.2 g of lidocaine base is dissolved in 5 ml of acetone. This solution can be utilized for the preparation of a single coating or multiple coatings.

What we claim is:

1. A dental composition which comprises an anti-osteoporotic agent, an antiphlogistic agent, optionally a natural or synthetic chemotherapeutic agent or local anaesthetic, furthermore one or more known auxiliary agent(s).

2. A composition as claimed in claim 1, which comprises ipriflavone (7-isopropoxy-isoflavone) as anti-osteoporotic agent, triamcinolone as antiphlogistic agent, an antibiotic, preferably doxycyclin or a salt thereof, a sulphonamide or trimethoprim as a chemotherapeutic agent and lidocaine as local anaesthetic.

3. A composition as claimed in claim 1 or 2, which comprises 0.1 to 30 % by weight of ipriflavone, 0.5 to 15 % by weight of triamcinolone, optionally 0.1 to 10 % by weight of doxycyclin or a salt thereof, optionally 1 to 20 % by weight of lidocaine, and 35 to 99.4 % by weight of one or more known auxiliary agent(s).

4. A process for the preparation of a dental composition, characterized in that 0.1 to 30 % by weight of ipriflavone, 0.5 to 15 % by weight of triamcinolone, optionally 0.1 to 10 % by weight of doxycyclin or a salt thereof and optionally 1 to 20 % by weight of lidocaine are admixed with 35 to 99.4 % by weight of one or more known auxiliary agent(s).

5. A method for protecting pulp of carious teeth, characterized in that a composition as claimed in claim 1 is utilized.


6. A method for preserving the vitality of pulp in early stages of pulpitis, characterized in that a composition as claimed in claim 1 is utilized.

7. A method for sterilizing pulp canal, characterized in that a composition as claimed in claim 1 is utilized.

8. A method for preparing a final root filling with the provision of an X-ray contrast agent, characterized
5 in that a composition as claimed in claim 1 is utilized.

INTERNATIONAL SEARCH REPORT

International Application No PCT/HU 88/00003

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : A 61 K 6/00				
II. FIELDS SEARCHED Minimum Documentation Searched ⁷				
Classification System	Classification Symbols			
Int.Cl. ⁴	A 61 K 6/00, 6/02			
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸				
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹				
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³		
A	DE, A1, 3 539 202 (LION CORP.) 22 May 1986 (22.05.86).	(1)		
A	DE, A1, 2 629 694 (TAKAHASHI et al.) 20 January 1977 (20.01.77).	(1)		
A	DE, A, 2 321 215 (MOCHIDA SEIYAKU) 15 November 1973 (15.11.73).	(1)		
A	DE, B, 1 202 937 (L.D.CAULK COMPANY) 14 October 1965 (14.10.65).	(1)		
A	DE, B, 1 195 436 (HAAS et al.) 24 June 1965 (24.06.65).	(1)		
A	DE, C, 667 808 (LINGNER-WERKE) 21 November 1938 (21.11.38).	(1)		
A	GB, A, 1 465 406 (SVEN-GUNNAR HESSELGREN) 23 February 1977 (23.02.77).	(1)		
A	US, A, 4 121 940 (MICHEL et al.) 24 October 1978 (24.10.78).	(1)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> • Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "G" document member of the same patent family </td> </tr> </table>			<ul style="list-style-type: none"> • Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "G" document member of the same patent family
<ul style="list-style-type: none"> • Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "G" document member of the same patent family 			
IV. CERTIFICATION				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report			
14 April 1988 (14.04.88)	25 April 1988 (25.04.88)			
International Searching Authority	Signature of Authorized Officer			
AUSTRIAN PATENT OFFICE				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	US, A, 3 913 229 (DRISKELL et al.) 21 October 1975 (21.10.75). -----	(1)

Anhang zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

Annex to the International Search Report on International Patent Application No. PCT/HU 88/00003

Annexe au rapport de recherche internationale relatif à la demande de brevet international n°.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned International search report. The Austrian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche internationale visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office autrichien des brevets.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
DE-A1-3 539 202	22/05/1986	GB-A1- 2 167 299 JP-A2-61-112 028 US-A - 4 725 428	29/05/1986 30/05/1986 16/02/1988
DE-A1-2 629 694 -B2- -C3-	20/01/1977 27/09/1979 04/06/1980	DK-A - 2 911/76 DK-B - 145 448 DK-C - 145 448 JP-A2-52-004 687 JP-B4-60-050 763 US-A - 4 080 212	31/12/1976 22/11/1982 18/04/1983 13/01/1977 11/11/1985 21/03/1978
DE-A -2 321 215	15/11/1973	CA-A1- 960 107 CH-A - 548 749 DE-A1- 2 259 490 BR-AO- 7 303 064 CA-A1- 1 032 692 FR-A1- 2 182 186 FR-B1- 2 182 186 GB-A - 1 426 901 JP-A2-49-005 143 JP-B4-51-037 092 US-A - 3 829 973	31/12/1974 15/05/1974 18/10/1973 29/08/1974 06/06/1978 07/12/1973 28/05/1976 03/03/1976 17/01/1974 13/10/1976 20/08/1974
DE-B -1 202 937	14/10/1965	None	
DE-B -1 195 436	24/06/1965	None	
DE-C - 667 808	21/11/1938	None	

GB-A-1 465 406	23/02/1977	DE-A1- 2 403 105	08/08/1974
		DK-B - 138 726	23/10/1978
		DK-C - 138 726	02/04/1979
		FR-A1- 2 215 970	30/08/1974
		FR-B1- 2 215 970	28/07/1978
		JP-A2-49-111 492	23/10/1974
		JP-B4-58-021 604	02/05/1983
		NL-A - 7 401 495	07/08/1974
		NO-B - 141 145	15/10/1979
		NO-C - 141 145	23/01/1980
		SE-B - 379 479	13/10/1975
		SE-C - 379 479	22/01/1976
		US-A - 3 964 164	22/06/1976
US-A-4 121 940	24/10/1978	CA-A1- 1 104 058	30/06/1981
		JP-A2-53-133 640	21/11/1978
US-A-3 913 229	21/10/1975	AU-A1- 78 422/75	26/08/1976
		BE-A1- 825 885	16/06/1975
		CA-A1- 1 042 801	21/11/1978
		CH-A - 604 701	15/09/1978
		DE-A1- 2 507 933	28/08/1975
		FR-A1- 2 261 749	19/09/1975
		FR-B3- 2 261 749	04/11/1977
		GB-A - 1 484 781	08/09/1977
		JP-A2-50-124 489	30/09/1975
		JP-B4-58-013 523	14/03/1983